Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel plus nedaplatin for platinum-resistant recurrent epithelial ovarian cancer
ChiCTR2000030875Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and nedaplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: objective response rate. Started Oct 2019; status: recruiting.
02
Drugs
paclitaxelnedaplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2000030875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030875.